Randomized Controlled Trial of Olanzapine for the Control of Chemotherapy-induced Vomiting in Children Receiving Cyclophosphamide-based Conditioning for Allogeneic Hematopoietic Stem Cell Transplant Save

Date Added
November 5th, 2019
PRO Number
Pro00091874
Researcher
Michelle Hudspeth

List of Studies


Profiles_link
Keywords
Cancer, Transplant
Summary

This study is for subjects that are about to receive high dose cyclophosphamide before a blood or bone marrow transplant (BMT). The investigational drug in this study is Olanzapine. This research is being done to find out whether adding olanzapine to standard medications will be helpful in controlling chemotherapy induced nausea in children. The total length of participation in this study will depend on how many days you are scheduled to receive chemotherapy, but can be up to a maximum of 2 weeks. We will review your chart for 100 days after transplant. There will be no extra visits to MUSC due to participating in the research study.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation Save

Date Added
August 7th, 2019
PRO Number
Pro00089654
Researcher
Amarendra Neppalli

List of Studies

Silhouette
Keywords
Cancer, Transplant
Summary

This study is for participants that require an allogenic peripheral blood stem cell transplant. The purpose of this study is to compare 2 combinations of drugs to prevent graft-versus-host disease (GVHD), a serious complication of a stem cell transplant. These combinations are either Tacrolimus/methotrexate or Tacrolimus/mycophenolate mofetil/cyclophosphamide. Doctors want to know which combination is better or if they give the same results. The study will help doctors decide which treatment is best at preventing GVHD for future transplant patients. Participants can expect to be in this study for up to 2 years after transplant.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation (ACES) PBMTC SUP1701 Save

Date Added
May 7th, 2019
PRO Number
Pro00084735
Researcher
Michelle Hudspeth

List of Studies


Profiles_link
Keywords
Cancer, Pediatrics, Transplant
Summary

This study is for patients that have had a Hematopoietic Stem Cell Transplant (HSCT) and still have persistent Cytomegalovirus (CMV), adenovirus and/or Epstein-Barr Virus (EBV) infection; or have a Primary Immunodeficiency Disorder (PID) with one or more viral infections that persist. The primary purpose of the study is to evaluate whether most closely HLA-matched multivirus-specific T cell lines obtained from a bank of allogeneic virus-specific T cell lines (VSTs) have antiviral activity against three viruses: EBV, CMV and adenovirus. Participants can expect to be on this study for about 12 months.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

The effect of conversion to once-daily Envarsus on the neurologic toxicity burden in liver transplant recipients Save

Date Added
April 9th, 2019
PRO Number
Pro00083855
Researcher
Derek Dubay

List of Studies

Silhouette
Keywords
Liver, Transplant
Summary

The aim of this study is to determine if a long-acting tacrolimus product can reduce the severity and incidence of several neurotoxicities commonly seen after liver transplant. The medications being used in this study are extended release tacrolimus (Envarsus) and immediate release tacrolimus (Prograf). Participants will receive SOC treatment for the first 6 months following transplant, and then randomized to either Envarsus or Prograf for the 6 month duration of the study. There are 9 study visits that will involve tests, exams and procedures that are both standard of care and study purposes.

Institution
MUSC
Recruitment Contact
Courtney Rowley
843-792-7082
rowle@musc.edu

Validating Cell-based Assays For ABMR After Renal Transplantation Save

Date Added
April 2nd, 2019
PRO Number
Pro00087322
Researcher
Vinayak Rohan

List of Studies

Silhouette
Keywords
Transplant
Summary

This study will evaluate a new blood test which can detect organ rejection in patients who have had a kidney transplant. Blood samples will be obtained from subjects after consent and again up to 90 days afterward to test for transplant rejection.

Institution
MUSC
Recruitment Contact
Caitlin Schaffner
843-792-7558
schaffne@musc.edu

APOL1 Long-term kidney transplantation outcomes network (APOLLO) Save

Date Added
February 19th, 2019
PRO Number
Pro00084947
Researcher
Derek Dubay

List of Studies

Silhouette
Keywords
Kidney, Transplant
Summary

Expression of APOL1 gene variants have been associated with higher likelihood of end stage renal disease in African Americans. In addition, kidney transplant recipients who have received a donated kidney from an African American expressing APOL1 variants have poorer outcomes with earlier transplanted kidney failure. This study will examine the occurance of the APOL1 gene variants in all African American donated kidneys, deceased and living, and African American recipients and recipients of African American donated kidneys, and to correlate the expression of these variants with outcome of the transplanted kidney and the kidney function of African American living donors. Samples of patients blood and urine will be acquired to measure the expression of the APOLO1 gene variants and associated kidney function, respectively.

Institution
MUSC
Recruitment Contact
Thomas Morinelli
8437925405
morinelt@musc.edu

Genetic Testing for non-diabetic nephropathy (apolipoprotein L1 gene): Attitudes of African American transplant patients, living donors, and non-transplant patients/non-donors Save

Date Added
February 7th, 2019
PRO Number
Pro00085244
Researcher
Prabhakar Baliga

List of Studies


Profiles_link
Keywords
Transplant
Summary

The purpose of this study is to better understand what people think about genetic testing for kidney transplant. The study will be conducted at 3 transplant research centers. Participants will be asked to fill out a questionnaire about attitudes toward genetic testing and will also be asked questions about how easy the survey itself is to understand.

Institution
MUSC
Recruitment Contact
Caitlin Schaffner
843-792-7558
schaffne@musc.edu

International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis Save

Date Added
February 5th, 2019
PRO Number
Pro00084129
Researcher
Jacqueline Kraveka

List of Studies


Profiles_link
Keywords
Adolescents, Cancer, Pediatrics, Transplant
Summary

This study is for patients that have been diagnosed with multisystem Langerhans cell histiocytosis (LCH). The purpose of this study is to find out if prolonging the treatment and adding a drug called 6-mercaptopurine will be beneficial. Other goals include fining out if these changes will result in fewer patients having relapse of their LCH, and fewer patients having long term disease related problems. Participants can expect to be in this study for up to 24 months and will be followed on this study fir at least 5 years.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

Human Samples Biorepository Save

Date Added
August 21st, 2018
PRO Number
Pro00072807
Researcher
Federica Del monte

List of Studies

Silhouette
Keywords
Aging, Cardiovascular, Coronary Artery Disease, Genetics, Heart, Military, Sarcoidosis, Scleroderma, Transplant, Vascular
Summary

The purpose of the study is to generate a bio bank of specimens for research. We will tissue that would otherwise be discarded from clinical or surgical procedure and information from medical records. We will also collect discarded blood, urines and sputum. Collecting samples will help to better understanding the mechanisms of cardiovascular diseases, identify biomarkers for early diagnosis and to predict safety and efficacy of new therapies.

Institution
MUSC
Recruitment Contact
Federica del Monte
843-792-8397
delmonte@musc.edu

Immune response to pneumococcal vaccination in aging renal transplant recipients Save

Date Added
June 19th, 2018
PRO Number
Pro00077548
Researcher
Maria anna Westerink

List of Studies

Silhouette
Keywords
Aging, Diabetes, Geriatrics, Healthy Volunteer Studies, Hypertension/ High Blood Pressure, Immune System, Kidney, Transplant, Vaccine
Summary

We will study how well the relatively new FDA approved pneumonia vaccine can protect older renal transplant recipients against pneumococcal illness. We will specifically study the group of renal transplants in whom the cause of renal failure was either diabetes mellitus II and/or hyoertension. We will compare the findings against those we find in younger renal transplant recipients, older healthy individuals and older persons with diabetes but normal kidney function. Healthy younger individuals will serve as controls for optimal vaccine response.

Institution
MUSC
Recruitment Contact
Myroslawa Happe
843-792-2218
soloshch@musc.edu

Change_preferences

-- OR --

Create_login